Advertisement

A Double-Blind Clinical Study in Patients with Herpes Zoster to Establish YN-72 (Brovavir) Dose

  • Michihito Niimura
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 278)

Abstract

YN-72 (bromovinyl araU, or BV-araU) is a new antiviral agent synthesized by Yamasa Shoyu Company. It is an arabinosyluracil derivative having a bromovinyl group at the 5 position. Its chemical structure is shown in figure 1. YN-72 had potent in vitro antiviral action against varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1). Its proliferation-depressing action on normal cells is very low, and therefore the antiviral agent is highly selective (1–6). The mechanism of action is as follows: YN-72 is phosphorylated only by viral thymidine kinase to become a monophosphate and diphosphate. It is converted to a triphosphate by cellular kinase, which antagonizes the action of DNA polymerase, inhibiting viral proliferation (7–10).

Keywords

Placebo Group Dose Group Herpes Zoster Effectiveness Rate Test Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Machida, H., Sakata, S., Kuninaka, A. and Yoshino, H. (1981) Antimicrob. Agents Chemother.20, 47–52.PubMedGoogle Scholar
  2. 2.
    Machida, H., Kuninaka, A. and Yoshino, H. (1982) Antimicrob. Agents Chemother.21, 358–361.PubMedGoogle Scholar
  3. 3.
    Machida, H. and Sakata, S. (1984) Antiviral Res. 4, 135–141.PubMedCrossRefGoogle Scholar
  4. 4.
    Shigeta, S., Yokota, T., Iwabuchi, T., Baba, M., Konno, K., Ogata, M. and De Clercq, E. (1983) J. Infect. Dis.147, 576–584.PubMedCrossRefGoogle Scholar
  5. 5.
    Soike, K. F., Baskin, G., Cantrell, C. and Gerone, P. (1984) Antiviral Res. 4, 245–257.PubMedCrossRefGoogle Scholar
  6. 6.
    Machida, H. (1986) Antimicrob. Agents Chemother.29, 524–526.PubMedGoogle Scholar
  7. 7.
    Cheng, Y.-C., Dutschman, G., Fox, J. J., Watanabe, K. A. and Machida, H. (1981) Antimicrob. Agents Chemother.20, 420–423.PubMedGoogle Scholar
  8. 8.
    Ruth, J. L., and Cheng, Y.-C. (1981) Mol. Pharmacol.20, 415–422.PubMedGoogle Scholar
  9. 9.
    Ayisi, N. K., Wall, R. A., Wanklin, R. J., Machida, H., De Clercq, E. and Sacks, S. L. (1987) MoL PhannacoL 31, 422–429.Google Scholar
  10. 10.
    Suzutani, T., Machida, H., Sakuma, T. and Azuma, M. (1988) Antimicrob. Agents Chemother.32, 1547–1551.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1990

Authors and Affiliations

  • Michihito Niimura
    • 1
  1. 1.Department of DermatologyJikei University School of MedicineMinato-ku, 105 TokyoJapan

Personalised recommendations